首页|低分子肝素联合医护一体化快速康复外科干预对结直肠癌术后下肢DVT的预防效果

低分子肝素联合医护一体化快速康复外科干预对结直肠癌术后下肢DVT的预防效果

扫码查看
目的 探究低分子肝素(LMWH)联合医护一体化快速康复外科(ERAS)干预对结直肠癌(CRC)术后下肢深静脉血栓(DVT)的预防效果。方法 回顾性收集2021年1月至2023年10月杭州市中医院CRC术后患者,根据干预方式分为联合干预组(LMWH联合ERAS)和对照组(LMWH)。本研究主要观察指标为下肢DVT的发生率。次要观察指标为干预前后凝血指标[D-二聚体(D-D)、凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)和纤维蛋白原(Fib)]变化;双侧胭静脉、髂外静脉和股静脉血流速度;术后肛门排气恢复时间、进食时间、下床活动时间和住院时间;术后并发症率和药物不良反应率。结果 研究共纳入患者110例,联合干预组和对照组各55例。两组患者的基线资料、干预前凝血相关指标及下肢静脉血流速度差异无统计学意义(P>0。05);干预7 d和14 d后,两组患者的TT、PT、APTT和Fib均干预前较升高,D-D水平较干预前下降(P<0。05)。两组的TT、PT和APTT差异无统计学意义(P>0。05),但联合干预组D-D水平较对照组下降(P<0。05),Fib水平较对照组升高(P<0。05)。干预14 d后,联合干预组的双侧胭静脉、髂外静脉和股静脉血流速度高于对照组(P<0。05);DVT的发生率更低(1。82%vs。7。27%),但差异无统计学意义(P=0。363)。联合干预组的术后肛门排气恢复时间、进食时间、下床活动时间和住院时间较观察组缩短(P<0。05)。两组患者在术后并发症和LMWH不良反应的发生率上差异无统计学意义(P>0。05)。结论 LMWH联合ERAS干预可以有效改善CRC术后患者高凝状态,提高下肢静脉血流速度,减少DVT发生率,促进术后康复,并具有较好的安全性。
Efficacy of low molecular weight heparin combined with intervention of integrated medical-nursing enhanced recovery after surgery in preventing deep vein thrombosis after colorectal cancer surgery
Objective To explore the preventive effect of low molecular weight heparin(LMWH)combined with integrated medical-nursing enhanced recovery after surgery(ERAS)intervention on postoperative deep vein thrombosis(DVT)in colorectal cancer(CRC)patients.Methods A retrospective collection of postoperative CRC patients at Hangzhou Hospital of Traditional Chinese Medicine from January 2021 to October 2023 was conducted.Patients were divided in the combined intervention group(LMWH combined with ERAS)and the control group(LMWH)based on the intervention methods.The primary observation indicators of this study was the incidence of lower extremity DVT.Secondary observation indicators included changes in coagulation parameters[D-dimer(D-D),thrombin time(TT),prothrombin time(PT),activated partial thromboplastin time(APTT),and fibrinogen(Fib)]before and after intervention;blood flow velocity in the bilateral popliteal,external iliac,and femoral veins;time to first postoperative anal gas passage,time to resume eating,time to get out of bed and length of hospital stay;postoperative complication rate and adverse drug reaction rate.Results A total of 110 patients were included in the study,with 55 in the combined intervention group and 55 in the control group.There were no statistically significant differences between the two groups in terms of baseline characteristics,coagulation-related indicators before intervention,and lower limb venous blood flow velocity(P>0.05).After 7 and 14 days of intervention,TT,PT,APTT,and Fib levels in both groups were higher compared to before the intervention,while D-D levels decreased(P<0.05).There were no significant differences in TT,PT,and APTT between the two groups(P>0.05),but the D-D level in the combined intervention group was lower than that in the control group(P<0.05),and the Fib level was higher than that in the control group(P<0.05).After 14 days of intervention,the blood flow velocities in the bilateral popliteal,external iliac,and femoral veins were higher in the combined intervention group than in the control group(P<0.05),and the incidence of DVT was lower(1.82%vs.7.27%),but the difference was not statistically significant(P=0.363).The combined intervention group had shorter postoperative time to first anal gas passage,resumption of eating,getting out of bed,and length of hospital stay compared to the control group(P<0.05).Finally,there were no statistically significant differences between the two groups in the incidence of postoperative complications and adverse reactions to LMWH(P>0.05).Conclusion The combined intervention of LMWH and ERAS can effectively improve the hypercoagulable state in postoperative CRC patients,increase the venous blood flow velocity in the lower limbs,reduce the incidence of DVT,promote postoperative recovery,and has good safety.

Low molecular weight heparinIntegrated medical-nursingEnhanced recovery after surgeryDeep vein thrombosisColorectal cancerThrombosis prevention

吴丽丽、张言涛

展开 >

杭州市中医院普外科(杭州 310007)

低分子肝素 医护一体化 快速康复外科 下肢深静脉血栓 结直肠癌 血栓预防

浙江省中医药科技计划项目

2024ZL661

2024

中国药师
国家药品监督管理局高级研修学院,武汉医药(集团)股份有限公司

中国药师

CSTPCD
影响因子:0.944
ISSN:1008-049X
年,卷(期):2024.27(8)